biofil chemicals reported a sharp divergence in its first-quarter FY27 financial results, with revenue surging 92% year-on-year to ₹1,235.02 lakh while net profit plummeted 95% to ₹10.91 lakh. The Board of Directors approved the unaudited standalone results on August 11, 2026, citing increased trading activities in the Chemical Division as the primary driver for top-line growth. Despite the robust revenue expansion, profitability contracted significantly as the Pharma Division posted a segment loss and 'Other Income' collapsed from ₹283.20 lakh in Q1FY26 to just ₹6.26 lakh. The company also disclosed that its manufacturing facility is undergoing renovation to comply with revised Schedule M regulations, with completion expected within three to six months.

The Board meeting held on August 11, 2026, addressed key governance matters alongside the financial approvals. Ashok Kumar Ramawat was continued as a Non-Executive Independent Director upon attaining the age of 75 years, based on recommendations from the Nomination and Remuneration Committee. The Board also approved the Board’s Report on Operations and the Corporate Governance Report for the year ended March 31, 2026. Additionally, the company scheduled its 41st Annual General Meeting for September 23, 2026, to be conducted via Video Conferencing or Other Audio-Visual Means (OAVM). In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published the results in newspapers including Free Press Mumbai & Indore and Choutha Sansar on August 12, 2026.

Financial Performance

Revenue from operations climbed to ₹1,235.02 lakh in Q1FY27, compared to ₹643.26 lakh in the corresponding quarter of the previous year. Total income stood at ₹1,241.28 lakh, up from ₹926.46 lakh in Q1FY26. However, this increase was largely offset by a drastic fall in other income, which dropped to ₹6.26 lakh from ₹283.20 lakh in the prior year period. Total expenses increased to ₹1,227.87 lakh from ₹650.21 lakh, primarily due to higher purchases of stock-in-trade and cost of materials consumed associated with expanded trading volumes. Consequently, Profit Before Tax fell to ₹13.41 lakh from ₹276.25 lakh, and Net Profit after tax declined to ₹10.91 lakh from ₹241.10 lakh.

Segment Analysis

The Chemical Division was the primary driver of revenue growth, contributing ₹921.62 lakh compared to ₹158.51 lakh in Q1FY26. This division generated a segment profit of ₹15.43 lakh. In contrast, the Pharma Division saw revenue decline to ₹313.40 lakh from ₹484.75 lakh and incurred a segment loss of ₹6.41 lakh, widening from a profit of ₹269.74 lakh in the previous year. This divergence highlights a strategic shift towards trading activities rather than manufactured pharma products during this quarter. Earnings Per Share (EPS) for the quarter stood at ₹0.07 (Basic and Diluted), down significantly from ₹1.48 in Q1FY26.

What the Numbers Show

The financial data reveals a structural shift in Biofil Chemicals’ operations during Q1FY27. While revenue nearly doubled, the nature of this growth is predominantly transactional, evidenced by the sharp rise in 'Purchases of stock-in-trade' and 'Cost of materials consumed'. The collapse in 'Other Income' from ₹283.20 lakh to ₹6.26 lakh suggests that the prior year’s profitability was partly supported by non-operational gains, which are no longer present. Furthermore, the Pharma Division’s transition from a high-margin profit center to a loss-making unit indicates ongoing operational challenges or strategic pausing, likely linked to the mentioned manufacturing facility upgrades. Investors should monitor whether the upcoming completion of Schedule M compliance will restore manufacturing-led margins in subsequent quarters. SEBI has also provided a special one-year window, from February 05, 2026, to February 04, 2027, for investors to re-lodge old physical share transfer deeds submitted before April 1, 2019, if they were rejected or not processed due to deficiencies.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE829A01014/0c4a4c87-ef98-49c5-ae4b-b80585a3f257.pdf

Biofil Chemicals & Pharmaceuticals Ltd has moved to retain Mr. Ashok Kumar Ramawat as a Non-Executive Independent Director beyond the statutory age limit of 75 years. The company’s Board of Directors approved the continuation on August 11, 2026, based on the recommendation of the Nomination and Remuneration Committee. This move ensures continuity in governance for a director with 46 years of experience in the pharmaceutical industry, though it requires explicit shareholder consent to remain valid under regulatory frameworks.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-PoD2/I/3762/2026 dated January 30, 2026. Specifically, the filing addresses Sub-Para 7 of Para A of Part A of Schedule III of the Listing Regulations, which mandates continuous disclosure of material events regarding directorships.

Mr. Ramawat’s tenure is contingent upon approval by shareholders through a Special Resolution at the company’s ensuing 41st Annual General Meeting, as required under Regulation 17(1A) of the Listing Regulations. Until this approval is granted, his continuation remains provisional. The Board meeting that approved this recommendation commenced at 04:30 P.M. and concluded at 05:30 P.M. on August 11, 2026.

Mr. Ramawat holds a Bachelor’s Degree in Science and brings 46 years of post-qualification experience with significant exposure to the pharmaceutical sector. He was originally appointed as a Non-Executive Independent Director effective August 25, 2020. The filing confirms that he is not related to any other Directors or Key Managerial Personnel of the company, ensuring independence in his role.

The company also confirmed compliance with BSE Circular No. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CML/2018/24, both dated June 20, 2018. These circulars require listed entities to confirm that directors are not debarred from holding office by SEBI or any other regulatory or statutory authority. The disclosure was submitted in both XBRL and PDF formats through the stock exchanges’ filing utilities within the prescribed time limits.

Governance Implications

The retention of senior independent directors beyond the age of 75 is a strategic governance decision often aimed at preserving institutional memory and sector-specific expertise. In this case, Mr. Ramawat’s four decades of experience in the pharmaceutical industry likely provide valuable oversight capabilities. However, the requirement for a Special Resolution underscores the regulatory emphasis on shareholder agency in such exceptions to standard tenure rules. Investors will have the opportunity to vote on this matter during the 41st Annual General Meeting, determining whether the Board’s recommendation aligns with their expectations for board composition and independence.